Compare iShares MSCI China ETF (MCHI) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI China ETF vs TransMedics Group Inc — how do they compare? iShares MSCI China ETF trades at $52.46 (market cap $5.94B), while TransMedics Group Inc trades at $77.83 (market cap $2.74B). The key difference: iShares MSCI China ETF is far larger — about 2.2× TransMedics Group Inc's market cap, and TransMedics Group Inc is more actively traded (949,331 versus 1,575,471). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI China ETF for 63 Days and TransMedics Group Inc for 24 Days on average.
| MCHI | TMDX | |
|---|---|---|
Market Cap | $5.94B | $2.74B |
Volume | 1,575,471 | 949,331 |
Sector | Broad Market / Factor | Health |
52-Week High | $65.59 | $150.42 |
52-Week Low | $50.48 | $61.99 |
Typical Hold Time | 63 Days | 24 Days |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHI trades at $52.46, up 1.59% today, but faces strong bearish technical signals with 13 sell signals on moving averages. The ETF's valuation remains historically cheap compared to US indices, with Seeking Alpha noting the discount despite significant tech exposure. Recent news highlights China's economic challenges including industrial overcapacity and trade tensions ahead of key US-China meetings.
Outlook remains cautious given bearish technicals and China's macroeconomic headwinds, though the valuation discount presents potential opportunity. Key risks include US-China trade tensions and weak domestic consumption. Institutional activity shows mixed signals with recent purchases by Empowered Funds offset by sales from Acima Private Wealth.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
